Novocure’s Optune Pax approved in Japan for unresectable locally advanced pancreatic cancer

Novocure announced MHLW approval of Optune Pax for unresectable locally advanced pancreatic cancer, to be used with gemcitabine and nab—paclitaxel.Key Highlights:Original SEC Filing: NovoCure Ltd [ NVCR ] - 8-K - Oct. 01, 2026This is an AI-powered summary. It may contain inaccuracies. Consider veri…